SCHEMBL6825869

SCHEMBL6825869

NC(=O)c1ccccc1-c1ncc[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1A1 P48729 1/20 1.00
TYRO3 Q06418 1/20 1.00
DYRK1B Q9Y463 1/20 1.00
NUDT1 P36639 1/20 0.55
PARP1 P09874 3/20 0.52
BCAT2 O15382 1/20 0.49
MTOR P42345 1/20 0.46
ADK P55263 1/20 0.46
NISCH Q9Y2I1 1/20 0.46
HCRTR1 O43613 2/20 0.46
HCRTR2 O43614 2/20 0.46
KMT2A Q03164 2/20 0.43
GRM5 P41594 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
BTK Q06187 1/20 0.42
IDO1 P14902 1/20 0.42
CHEK1 O14757 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL30473073 0.98 CSNK1A1 (0.97) CSNK1A1TYRO3DYRK1BNUDT1PARP1
SCHEMBL10714674 0.86 CSNK1A1 (0.76) CSNK1A1TYRO3DYRK1BNUDT1PARP1
SCHEMBL297622 0.85 CSNK1A1 (0.73) CSNK1A1TYRO3DYRK1BMTORADK
SCHEMBL30965100 0.85 CSNK1A1 (0.73) CSNK1A1TYRO3DYRK1BMTORADK
SCHEMBL4564865 0.84 CSNK1A1 (0.73) CSNK1A1TYRO3DYRK1BNUDT1PARP1
SCHEMBL15478263 0.83 CSNK1A1 (0.71) CSNK1A1TYRO3DYRK1BPARP1MTOR
SCHEMBL31661863 0.83 CSNK1A1 (0.71) CSNK1A1TYRO3DYRK1BNUDT1PARP1
SCHEMBL11566235 0.83 CSNK1A1 (0.71) CSNK1A1TYRO3DYRK1BNUDT1PARP1
SCHEMBL9234252 0.83 CSNK1A1 (0.71) CSNK1A1TYRO3DYRK1BNUDT1PARP1
Hydrochloric Acid SCHEMBL5854599 0.83 CSNK1A1 (0.71) CSNK1A1TYRO3DYRK1BMTORADK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106897-A1 METHODS AND COMPOSITIONS FOR CREATING INDUCED PLURIPOTENT STEM CELLS COLOSSAL BIOSCIENCES INC. (US) 2025-05-22 WO disclosed
WO-2023240157-A2 COMPOSITIONS AND METHODS FOR THE TARGETING OF DMD SCRIBE THERAPEUTICS INC. (US) 2023-12-14 WO disclosed
CN-107428740-A Indazolyl-and indolyl-benzamide derivatives 埃萨内克斯股份有限公司 2017-12-01 CN disclosed
CN-104105545-B preparation of olefin oligomerization catalyst 切弗朗菲利浦化学公司 2017-07-04 CN disclosed
CN-104105545-A Preparation of olefin oligomerization catalyst CHEVRON PHILLIPS CHEMICAL COMOANY LP 2014-10-15 CN disclosed
US-8772507-B2 Imidazole-benzamide anti-cancer agents CYTOKINETICS, INC. (US) 2014-07-08 US disclosed
US-8252831-B2 Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis ELI LILLY AND COMPANY (US) 2012-08-28 US disclosed
US-20120157506-A1 Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis ELI LILLY AND COMPANY (US) 2012-06-21 US disclosed
CN-101218234-B Phenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2011-12-14 CN disclosed
CN-100484935-C benzimidazole derivatives as factor Xa inhibitors SANOFI AVENTIS DEUTSCHLAND (DE) 2009-05-06 CN disclosed
CN-101218234-A Phenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMACEUTICALS SA (CH) 2008-07-09 CN disclosed
CN-101139346-A Benzimidazole-derivatives as factor Xa inhibitors SANOFI AVENTIS DEUTSCHLAND (DE) 2008-03-12 CN disclosed
CN-1791598-A benzimidazole derivatives as factor Xa inhibitors SANOFI AVENTIS DEUTSCHLAND (DE) 2006-06-21 CN disclosed
WO-2004089877-A1 NEW HYDROXYNAPHTHYL AMIDES ASTRAZENECA AB (SE) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157506-A1 Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis ARG2, HDAC6, COL2A1 CSNK1A1 2093/4885TYRO3 774/4885DYRK1B 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.